非酒精性脂肪性肝病与结直肠癌

doi:10.3969/j.issn.1672-5069.2018.01.043

Abstract

Abstract: Nonalcoholic fatty liver disease （NAFLD） is the hepatic manifestation of obecity and metabolic syndrome （MS）. Recently, more and more studies have shown the NAFLD is closely related to the occurrence of colorectal cancer （CRC）. The insulin resistance and systemic low-grade inflammation in the process of NAFLD may be involved in the carcinogenesis of colorectal adenoma and CRC. However, the mechanism by which the NAFLD increase the risk of CRC is not fully understood. In this article, we reviews the possible mechanisms NAFLD increase the colorectal adenomas and CRC occurrence.

Key words: Nonalcoholic fatty liver disease, Colorectal cancer, Insulin resistance, Metabolic syndrome

Xu Yan, Shi Cuicui, Fan Jiangao. What role the nonalcoholic fatty liver disease play in carcinogenesis of colorectal cancer[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(1): 149-152.

References

[1] Byrne CD,Targher G. Ectopic fat,insulin resistance,and nonalcoholic fatty liver disease:implications for cardiovascular disease. Arterioscler Thromb Vasc Biol,2014. 34（6）:1155-1161.
[2] Fan JG,Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol,2009,50（1）:204-210.
[3] Torre LA,Bray F,Siegel RL,et al. Global cancer statistics,2012. CA Cancer J Clin,2015,65（2）:87-108.
[4] Sung JJ,Lau JY,Goh KL,et al. Increasing incidence of colorectal cancer in Asia:implications for screening. Lancet Oncol,2005,6（11）:871-876.
[5] McKeown-Eyssen G. Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk. Cancer Epidemiol Biomarkers Prev,1994,3（8）:687-695.
[6] Hwang ST,Cho YK,Park JH,et al. Relationship of non-alcoholic fatty liver disease to colorectal adenomatous polyps. J Gastroenterol Hepatol. 2010. 25（3）:562-567.
[7] Aktas E,Uzman M,Yildirim O,et al. Assessment of hepatic steatosis on contrast enhanced computed tomography in patients with colorectal cancer. Int J Clin Exp Med,2014,7（11）:4342-4346.
[8] 陈羽,袁瑜,朱彦华,等. 非酒精性脂肪性肝病并发结直肠粘膜癌变的临床特征. 实用肝脏病杂志,2012,15（6）:557-558.
[9] Wong VW,Wong GL,Tsang SW,et al. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut,2011,60（6）:829-836.
[10] Ahn JS,Sinn DH,Min YW,et al. Non-alcoholic fatty liver diseases and risk of colorectal neoplasia. Aliment Pharmacol Ther,2017,45（2）:345-353.
[11] 王菲,王允野. 非酒精性脂肪性肝病并结直肠息肉发病特点研究. 中国实用医药,2015,13（12）:39-40.
[12] Lee YI,Lim YS,Park HS. Colorectal neoplasms in relation to non-alcoholic fatty liver disease in Korean women:a retrospective cohort study. J Gastroenterol Hepatol. 2012,27（1）: 91-95.
[13] Karube H,Masuda H,Hayashi S,et al. Fatty liver suppressed the angiogenesis in liver metastatic lesions. Hepatogastroentero-
logy,2000,47（36）:1541-1545.
[14] Min YW,Yun HS,Chang WI,et al. Influence of non-alcoholic fatty liver disease on the prognosis in patients with colorectal cancer. Clin Res Hepatol Gastroenterol,2012,36（1）:78-83.
[15] Touzin NT,Bush KN,Williams CD,et al. Prevalence of colonic adenomas in patients with nonalcoholic fatty liver disease. Therap Adv Gastroenterol,2011,4（3）:169-176.
[16] Stadlmayr A,Aigner E,Steger B,et al. Nonalcoholic fatty liver disease:an independent risk factor for colorectal neoplasia. J Intern Med,2011,270（1）:41-49.
[17] Sanna C,Rosso C,Marietti M,et al. Non-alcoholic fatty liver disease and extra-hepatic cancers. Int J Mol,Sci,2016,17（5）:1232-1236.
[18] Basyigit S,Uzman M,Kefeli A,et al. Absence of non-alcoholic fatty liver disease in the presence of insulin resistance is a strong predictor for colorectal carcinoma. Int J Clin Exp Med,2015,8（10）:18601-18610.
[19] Alam S,Mustafa G,Alam M,et al. Insulin resistance in development and progression of nonalcoholic fatty liver disease. World J Gastrointest Pathophysiol,2016,7（2）:211-217.
[20] Adams LA,Harmsen S,St SJL,et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes:a community-based cohort study. Am J Gastroenterol,2010,105（7）:1567-1573.
[21] Wong MC,Ching JY,Chan VC,et al. Screening strategies for colorectal cancer among patients with nonalcoholic fatty liver disease and family history. Int J Cancer,2016,138（3）:576-583.
[22] Bhatt BD,Lukose T,Siegel AB,et al. Increased risk of colorectal polyps in patients with non-alcoholic fatty liver disease undergoing liver transplant evaluation. J Gastrointest Oncol,2015,6（5）:459-468.
[23] Huang KW,Leu HB,Wang YJ,et al. Patients with nonalcoholic fatty liver disease have higher risk of colorectal adenoma after negative baseline colonoscopy. Colorectal Dis,2013,15（7）:830-835.
[24] Muhidin SO,Magan AA,Osman KA,et al. The relationship between nonalcoholic fatty liver disease and colorectal cancer: the future challenges and outcomes of the metabolic syndrome. J Obes. 2012,2012:637538.
[25] Mikolasevic I,Milic S,Orlic L,et al. Factors associated with significant liver steatosis and fibrosis as assessed by transient elastography in patients with one or more components of the metabolic syndrome. J Diabetes Complications,2016,30（7）:1347-1353.
[26] Lee J,Meyerhardt JA,Giovannucci E,et al. Association between body mass index and prognosis of colorectal cancer:a meta-analysis of prospective cohort studies. PLoS One,2015,10（3）:e0120706.
[27] Tabuchi M,Kitayama J,Nagawa H. Hypertriglyceridemia is positively correlated with the development of colorectal tubular adenoma in Japanese men. World J Gastroenterol,2006,12（8）:1261-1264.
[28] Bonovas S,Filioussi K,Flordellis CS,et al. Statins and the risk of colorectal cancer:a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol. 2007. 2（23）:3462-3468.
[29] Wong VW,Hui AY,Tsang SW,et al. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol,2006,4（9）1154-1161.
[30] Fotbolcu H,Zorlu E. Nonalcoholic fatty liver disease as a multi-systemic disease. World J Gastroenterol,2016,22（16）4079-4090.
[31] Wong VW,Wong GL,Tsang SW,et al. Genetic polymorphisms of adiponectin and tumor necrosis factor-alpha and nonalcoholic fatty liver disease in Chinese people. J Gastroenterol Hepatol,2008,23（6）:914-921.
[32] Wei EK,Giovannucci E,Fuchs CS,et al. Low plasma adiponectin
levels and risk of colorectal cancer in men:a prospective study. J Natl Cancer Inst,2005,97（22）:1688-1694.
[33] Yamaji T,Iwasaki M,Sasazuki S,et al. Interaction between adiponectin and leptin influences the risk of colorectal adenoma. Cancer Res,2010,70（13）:5430-5437.
[34] Aleksandrova K,Boeing H,Jenab M,et al. Metabolic syndrome and risks of colon and rectal cancer:the European prospective investigation into cancer and nutrition study. Cancer Prev Res （Phila）,2011,4（11）:1873-1883.
[35] Sandhu MS,Dunger DB,Giovannucci EL. Insulin,insulin-like growth factor-I（IGF-I）,IGF binding proteins,their biologic interactions,and colorectal cancer. J Natl Cancer Inst,2002,94（13）: 972-980.
[36] Williams AC,Collard TJ,Perks CM,et al. Increased p53-dependent apoptosis by the insulin-like growth factor binding protein IGFBP-3 in human colonic adenoma-derived cells. Cancer Res,2000,60（1）:22-27.
[37] Ferroni P,Palmirotta R,Spila A,et al. Prognostic significance of adiponectin levels in non-metastatic colorectal cancer. Anticancer Res,2007,27（1B）:483-489.
[38] Procaccini C,Galgani M,De Rosa V,et al. Leptin:the prototypic adipocytokine and its role in NAFLD. Curr Pharm Des,2010,16（17）:1902-1912.
[39] Tilg H,Diehl AM. NAFLD and extrahepatic cancers: have a look at the colon. Gut,2011,60（6）:745-746.
[40] Zauber AG,Winawer SJ,O'Brien MJ,et al. Colonoscopic polypec-
tomy and long-term prevention of colorectal-cancer deaths. N Engl J Med,2012,366980:687-696.
[41] Tuan J,Chen YX. Dietary and lifestyle factors associated with colorectal cancer risk and interactions with microbiota:Fiber,red or processed meat and alcoholic drinks. Gastrointest Tumors,2016,3（1）:17-24.
[42] 曹海霞,范建高. 非酒精性脂肪性肝病的饮食治疗.实用肝脏病杂志,2014,17（5）:452-455.

What role the nonalcoholic fatty liver disease play in carcinogenesis of colorectal cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[2]	Ren Yufei, Chen Xiaoqing, Kong Weizong, et al.. Effect of salvianolic acid B on autophagy in nonalcoholic fatty liver disease cell model in vitro [J]. Journal of Practical Hepatology, 2019, 22(6): 804-807.
[3]	Li Yingyi, Guo Cuifen, Zhang Ruinan, et al.. Correlation of polymorphism of ALDH2 rs671 to morbidity in individuals prone to nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(6): 848-851.
[4]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[5]	Zhang Lanhua, Shao Qin, Xia Zhenjuan. Changes of serum 25-(OH) D3 and IL-17 levels are associated with progress of nonalcoholic fatty liver disease in obese children [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 522-525.
[6]	Huo Huiqin, Gong Xiaohong, Li Zhenghong. Assessment of right atrial and ventricular functions in patients with nonalcoholic fatty liver disease-induced liver cirrhosis by real-time three-dimensional echocardiography and speckle tracking imaging [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 244-247.
[7]	Xie Xiao, Lu Lungen. Noninvasive diagnosis and assessment of patients with nonalcoholic steatohepatitis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 301-306.
[8]	Zhang Feng, Yan Yan.. Implication of serum apolipoprotein B levels and its correlation with metabolic syndrome in checked-up individuals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 61-64.
[9]	Xu Jian, Lu Xiangyu, Gong Jun, et al.. Prevalence of metabolic syndrome and new-onset cholelithiasis in the elderly [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 133-136.
[10]	Zhong Yan, Su Shuting, Mi Yuqiang.. Treatment of patients with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 145-148.
[11]	Huang Jiaofeng, Lin Su, Wang Mingfang, et al.. Impact of entecavir therapy on hepatic steatosis in patients with chronic hepatitis B and nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 863-867.
[12]	Dong Xuelian, Zhang Wenjun.. Application of controlled attenuation parameter in screening individuals with risk of metabolic syndrome [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 868-871.
[13]	Huang Faguang, Li Xiaocheng, Gong Jianping, et al.. Research on insulin resistance related protein molecules in human liver tissues by comprehensive gene expression profiling analysis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 872-876.
[14]	Pu Yonglan, Chen Yuanwen, Fan Jiangao.. Gluten intestinal disease and nonalcoholic fatty liver: One case report [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 981-982.
[15]	Ge Jianxiang, Sun Yezi, Zhao Yun.. Application of entecavir in the treatment of patients with HBV-related cirrhosis complicated by hepatogenous diabetes and its influence on indexes of glucose metabolism [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 677-680.